BR112023001336A2 - Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina) - Google Patents

Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina)

Info

Publication number
BR112023001336A2
BR112023001336A2 BR112023001336A BR112023001336A BR112023001336A2 BR 112023001336 A2 BR112023001336 A2 BR 112023001336A2 BR 112023001336 A BR112023001336 A BR 112023001336A BR 112023001336 A BR112023001336 A BR 112023001336A BR 112023001336 A2 BR112023001336 A2 BR 112023001336A2
Authority
BR
Brazil
Prior art keywords
cysteine
protein
glycine
gene therapy
rich
Prior art date
Application number
BR112023001336A
Other languages
English (en)
Inventor
Dean Herzog Christopher
Bittencort Sacramento Chester
Prabhakar Raj
Ricks David
Original Assignee
Spacecraft Seven Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spacecraft Seven Llc filed Critical Spacecraft Seven Llc
Publication of BR112023001336A2 publication Critical patent/BR112023001336A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)

Abstract

TERAPIA GÊNICA DE CSRP3 (PROTEÍNA 3 RICA EM CISTEÍNA E GLICINA). Uma terapia gênica para déficits gênicos relacionados a CSRP3 (Proteína 3 Rica em Cisteína e Glicina) associados à cardiomiopatia, por exemplo, usando um vetor de vírus adeno-associado (AAV) é fornecida neste documento. O promotor do vetor pode ser um promotor de MHCK7 ou um promotor de troponina cardíaca T (HTNNT2). O capsídeo pode ser um capsídeo de AAV9 ou AAVrh74 ou uma variante funcional do mesmo. Outros promotores ou capsídeos podem ser usados. São fornecidos ainda métodos de tratamento, tais como por administração intravenosa, intracoronária, intracarotídea ou intracardíaca do vetor rAAV e outras composições e métodos.
BR112023001336A 2020-08-05 2021-08-03 Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina) BR112023001336A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061727P 2020-08-05 2020-08-05
PCT/US2021/044412 WO2022031756A1 (en) 2020-08-05 2021-08-03 Csrp3 (cysteine and glycine rich protein 3) gene therapy

Publications (1)

Publication Number Publication Date
BR112023001336A2 true BR112023001336A2 (pt) 2023-02-14

Family

ID=80118758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023001336A BR112023001336A2 (pt) 2020-08-05 2021-08-03 Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina)

Country Status (11)

Country Link
US (1) US20230257431A1 (pt)
EP (1) EP4192962A1 (pt)
JP (1) JP2023536618A (pt)
KR (1) KR20230042468A (pt)
CN (1) CN116234916A (pt)
AU (1) AU2021321410A1 (pt)
BR (1) BR112023001336A2 (pt)
CA (1) CA3184983A1 (pt)
IL (1) IL300187A (pt)
MX (1) MX2023000994A (pt)
WO (1) WO2022031756A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230043869A (ko) 2020-08-07 2023-03-31 스페이스크래프트 세븐, 엘엘씨 Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
WO2023159190A1 (en) * 2022-02-18 2023-08-24 Ginkgo Bioworks, Inc. Gene therapy for arrhythmogenic cardiomyopathy
WO2023178337A2 (en) * 2022-03-18 2023-09-21 University Of Florida Research Foundation, Incorporated Methods and compositions for treating rbm20 related cardiomyopathy with a viral vector

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2615180T3 (es) 2007-07-14 2017-06-05 University Of Iowa Research Foundation Métodos y composiciones para el tratamiento de enfermedades cerebrales
EP3561062A1 (en) 2013-09-13 2019-10-30 California Institute of Technology Selective recovery
HUE054768T2 (hu) 2014-05-02 2021-09-28 Genzyme Corp AAV vektorok retina és CNS génterápiára
WO2017100671A1 (en) 2015-12-11 2017-06-15 California Institute Of Technology TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
BR112020024935A2 (pt) * 2018-06-08 2021-03-09 University Of Florida Research Foundation, Incorporated Terapia gênica cardíaca com aav para cardiomiopatia

Also Published As

Publication number Publication date
EP4192962A1 (en) 2023-06-14
IL300187A (en) 2023-03-01
MX2023000994A (es) 2023-03-01
US20230257431A1 (en) 2023-08-17
CA3184983A1 (en) 2022-02-10
WO2022031756A1 (en) 2022-02-10
CN116234916A (zh) 2023-06-06
KR20230042468A (ko) 2023-03-28
JP2023536618A (ja) 2023-08-28
AU2021321410A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
BR112023001336A2 (pt) Terapia gênica de csrp3 (proteína 3 rica em cisteína e glicina)
BR112023001852A2 (pt) Terapia gênica com placofilina-2 (pkp2) usando vetor de aav
BR112021019821A2 (pt) Sorotipo de vírus adenoassociado híbrido recombinante com modificação peptídica entre aav9 e aavrh74 com tropismo hepático reduzido e transdução muscular aumentada
BR112021020054A2 (pt) Capsídeos de vírus adeno-associado (aav) e composições contendo os mesmos
BR112021018776A2 (pt) Vetores de vírus adenoassociado recombinante
BR112022021134A2 (pt) Vírus adeno-associado com capsídeo projetado
WO2019060454A3 (en) Adeno-associated virus variant capsids and methods of use thereof
BR112021020957A2 (pt) Capsídeos de vírus adenoassociado (aav) variante para liberação intravítrea
BR112022022212A2 (pt) Composições para redução específica de drg de expressão de transgene
CL2021002236A1 (es) Inserción de vectores de virus adeno-asociados de b-sarcoglicano y el tratamiento de distrofia muscular
MX2022000551A (es) Proteínas de la cápside de aav modificadas para el tratamiento de una enfermedad artrítica.
BR112023002904A2 (pt) Vírus adenoassociado recombinante para tratar neurodegeneração com início na idade adulta associada a grn
BR112023001418A2 (pt) Vetor viral adeno-associado para expressão de glut1 e seus usos
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112022026521A2 (pt) Vetor viral, célula isolada, composição farmacêutica, uso de um vetor viral, método, e, método para prevenir ou tratar uma doença renal
AR122289A1 (es) Terapia genética cardíaca con aav para la cardiomiopatía en humanos
CL2023001876A1 (es) Proteínas de la cápside viral con especificidad para las células del tejido cardiaco
EA202290001A1 (ru) Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута
BR112022019304A2 (pt) Variantes de capsídeo de aav e usos das mesmas
IL259178B (en) A vector encoding ano5 for the treatment of muscular dystrophy
JP2018538261A5 (pt)
BR112022022704A2 (pt) Composições úteis para tratamento da doença de pompe
BR112022021762A2 (pt) Composições úteis em tratamento de distúrbio de deficiência de cdkl5 (cdd)
BR112022011332A2 (pt) Vetor de vírus adeno-associado recombinante, vírus adeno-associado recombinante, e, método para tratar um indivíduo com síndrome de hunter
JP2018533976A5 (pt)